Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Niculescu

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2001
Thymitaq (Zarix)I Niculescu-Duvaz
Idrugs : the Investigational Drugs Journal|May 10, 2008
Recent advances in anticancer drugsI Niculescu Duvaz
Idrugs : the Investigational Drugs Journal|July 21, 2005
NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The NetherlandsI Niculescu-Duvaz
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gemtuzumab ozogamicin, Celltech GroupI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
ZD-9331 AstraZenecaI Niculescu-Duvaz
Expert Opinion on Investigational Drugs|June 1, 1997
Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinationsI Niculescu-Duvaz, C J Springer
Anti-Cancer Drug Design|July 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugsC J Springer, I Niculescu-Duvaz
Cancer Treatment Reports|December 1, 1978
Potential anticancer agents. XVII. New developments in the benzoic acid nitrogen mustards areaI Niculescu-Duvăz, V Feyns, V Dobre
Carcinogenesis|April 1, 1985
QSAR application in chemical carcinogenesis. II. QSAR analysis of a class of carcinogenesis inhibitor: retinoidsI Niculescu-Duvăz, Z Simon, N Voiculeţ
AJNR. American Journal of Neuroradiology|August 1, 2020
COVID-19 and Involvement of the Corpus Callosum: Potential Effect of the Cytokine Storm?C Rasmussen, I Niculescu, S Patel, et al.
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2001
Thymitaq (Zarix)I Niculescu-Duvaz
Idrugs : the Investigational Drugs Journal|May 10, 2008
Recent advances in anticancer drugsI Niculescu Duvaz
Idrugs : the Investigational Drugs Journal|July 21, 2005
NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The NetherlandsI Niculescu-Duvaz
Current Opinion in Molecular Therapeutics|March 16, 2001
Technology evaluation: gemtuzumab ozogamicin, Celltech GroupI Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|March 16, 2001
ZD-9331 AstraZenecaI Niculescu-Duvaz
Expert Opinion on Investigational Drugs|June 1, 1997
Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinationsI Niculescu-Duvaz, C J Springer
Anti-Cancer Drug Design|July 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugsC J Springer, I Niculescu-Duvaz
Cancer Treatment Reports|December 1, 1978
Potential anticancer agents. XVII. New developments in the benzoic acid nitrogen mustards areaI Niculescu-Duvăz, V Feyns, V Dobre
Carcinogenesis|April 1, 1985
QSAR application in chemical carcinogenesis. II. QSAR analysis of a class of carcinogenesis inhibitor: retinoidsI Niculescu-Duvăz, Z Simon, N Voiculeţ
AJNR. American Journal of Neuroradiology|August 1, 2020
COVID-19 and Involvement of the Corpus Callosum: Potential Effect of the Cytokine Storm?C Rasmussen, I Niculescu, S Patel, et al.
Pageof 11